Thymol on Netrin-1 on Obese Patients

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The prevalence of obesity in Mexico is 35.4%, and it is considered a risk factor for the development of diabetes, systemic arterial hypertension and dyslipidemia. Obesity due to the increased distribution and growth of adipose tissue creates a pro-inflammatory state induced by molecules secreted by the adipocytes themselves. Netrin-1 is a cell migration protein, which directs the recruitment, migration and entrapment of macrophages in different tissues, within adipose tissue the entrapment of macrophages induces the release of pro-inflammatory cytokines, which increase the secretion of pro-inflammatory adipokines. It has been found in high concentration in patients with obesity, insulin resistance and type 2 diabetes. Thymol is a phytopharmaceutical derived from oregano oil that has shown powerful anti-inflammatory and antioxidant effects through the stimulation of PPAR-gamma, adiponectin and inhibition of the NF-κB pathway mediated by the JNK pathway, pathways in which netrin-1 is involved in macrophage entrapment and recruitment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centro Universitario de Ciencias de la Salud, Mexico
• Treatments: Thymol

Criteria

Inclusion Criteria:

• Subjects between 18 and 35 years old.

• BMI ≥ 30.0 and ≤35.0

• Systolic blood pressure less than 135 mmHg.

• Diastolic blood pressure less than 85 mmHg.

Exclusion Criteria:

• Subjects who are known to have a diagnosis, receive treatment, or are observed with:

• Rheumatological and / or thyroid disease.

• Chronic kidney disease and / or CKD-EPI glomerular filtration rate less than 60 ml / min / 1.72m2.

• Innate alterations of metabolism.

• Elevation of transaminases 2 times higher than normal.

• Total cholesterol greater than 250 mg / dl.

• Triglycerides greater than 300 mg / dl.

• Subjects presenting with acute illness, hospitalization, or drug treatment presented in the last 12 weeks prior to the study selection visit.

• Subjects with symptoms consistent with the definition of a probable case of COVID-19, as well as any subject with a diagnosis of COVID-19.

• Subjects who have had blood transfusions in the last 3 months.

• Regular smokers.

• Pregnant or lactating women.

• Women with a desire for pregnancy or who do not have a double barrier or progestin-only contraceptive method.